Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients (age 18 years and older) who have tested positive or suspected/presumed positive for CoViD-19 using PCR real time test~2. Patients with cough, shortness of breath or respiratory compromise (RR\>24/min, increased work of breathing.)~3. O2 Saturation less than or equal to 96% on room air or sensation~4. Agrees to use the gammaCore Sapphire device as intended and to follow all of the requirements of the study including recording required study data~5. Permission for early am blood draw to freeze for subsequent lab tests and sequencing as related to CoViD-19 sequelae~6. Patient is able to provide signed and witnessed Informed Consent~Exclusion Criteria:~1. On home/therapy oxygen (i.e. for chronic obstructive pulmonary disease (COPD) patients) at baseline prior to development of CoViD-19~2. Already using gammaCore® (nVNS) for other medical conditions~3. A history of aneurysm, intracranial hemorrhage, brain tumors, or significant head trauma~4. Known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (e.g., bruits or history of transient ischemic attack or cerebrovascular accident), congestive heart failure, known severe coronary artery disease, myocardial infarction documented within past 90 days, or current or recent history of life-threatening arrhythmia (sustained ventricular tachycardia, ventricular fibrillation, second or third-degree heart block, uncontrolled atrial fibrillation or uncontrolled atrial flutter)~5. Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia (as per investigator discretion)~6. Current implantation of an electrical and/or neurostimulator device, including but not limited to a cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant~7. Current implantation of metal cervical spine hardware or a metallic implant near the gammaCore® stimulation site~8. Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self-assessments is compromised (e.g. homeless, developmentally disabled and prisoner)~9. Compromised access to peripheral veins for blood sampling.~10. Pregnant women~11. Patients with active cancer or those who have had recent cancer treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gammaCore Sapphire® (nVNS) plus standard of care (Type: EXPERIMENTAL): Subjects will be administered study treatment with the nVNS device 3 times per day (prophylaxis) and also as needed for acute respiratory symptoms.
- standard of care alone (Type: ACTIVE_COMPARATOR): Will receive standard of care therapies to treat CoViD-19 infection and symptoms

Based on this trial design, predict the completion outcome and termination type (if applicable).